微创胰十二指肠切除术治疗胰腺癌的证据有限。这项回顾性分析评估了2016年4月至2023年4月接受机器人胰十二指肠切除术（RPD）或腹腔镜胰十二指肠切除术（LPD）的患者。他们的基线和围手术期数据，包括手术时间、R0分析手术切除率、严重并发症发生率，并收集无病生存率（DFS）、总生存率（OS）等随访数据。共进行LPD和RPD 253例，纳入胰腺癌101例，其中LPD 54例，RPD 47例。 RPD 组的转化率（4.3% vs. 29.6%，p = 0.001）和失血量（400 vs. 575 mL，p < 0.05）较低。两组在手术时间、血管切除率和TNM分期诊断方面无显着差异；然而，RPD 组的 R0 切除率（80.9% 比 70.4%）和淋巴结采集率（24.2 比 21.9）具有更高的趋势，并且 RPD 组的术后住院时间较短（11 天比 13 天） 。此外，1 至 3 年 DFS（75.7%、61.7% 和 36.0% vs. 59.0%、35.6% 和 21.9%）和 OS（94.7%、84.7% 和 50.8% vs. 84.1%、63.6）有所改善与 LPD 组相比，RPD 组有 45.5% 和 45.5% 的差异。 RPD 与 LPD 相比在手术安全性和肿瘤学结局方面具有优势，但在围手术期结局方面与后者相似。长期结果需要进一步研究。© 2024。外科肿瘤学会。

Evidence is limited for the treatment of pancreatic cancer among minimally invasive pancreatoduodenectomy.This retrospective analysis evaluated patients who underwent robotic pancreaticoduodenectomy (RPD) or laparoscopic pancreaticoduodenectomy (LPD) from April 2016 to April 2023. Their baseline and perioperative data, including operative time, R0 resection rates, and severe complications rates, were analyzed, and the follow-up data, such as disease-free survival (DFS) and overall survival (OS), were collected.A total of 253 cases of LPD and RPD were performed, and 101 cases with pancreatic cancer were included, of which 54 were LPD and 47 were RPD. The conversion rate (4.3% vs. 29.6%, p = 0.001) and blood loss (400 vs. 575 mL, p < 0.05) were lower in the RPD group. No significant difference was observed between the two groups in terms of operative time, vessel resection rates, and TNM-stage diagnosis; however, R0 resection rates (80.9% vs. 70.4%) and lymph node harvest (24.2 vs. 21.9) had a higher tendency in the RPD group, and postoperative length of stay was shorter in the RPD cohort (11 vs. 13 days). Moreover, improved 1- to 3-years DFS (75.7%, 61.7%, and 36.0% vs. 59.0%, 35.6%, and 21.9%) and OS (94.7%, 84.7%, and 50.8% vs. 84.1%, 63.6%, and 45.5%) was found in the RPD group in comparison with the LPD group.RPD had advantages in surgical safety and oncological outcomes compared with LPD, but was similar to the latter in perioperative outcomes. Long-term outcomes require further study.© 2024. Society of Surgical Oncology.